Overview

Investigate the Effect of AZD1656 on the Pharmacokinetics of Sitagliptin in Patients With Type 2 Diabetes Mellitus

Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to evaluate the effects of AZD1656 on Sitagliptin pharmacokinetics and vice versa in patients with Type 2 Diabetes Mellitus.
Phase:
Phase 1
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
AstraZeneca
Treatments:
Sitagliptin Phosphate
Criteria
Inclusion Criteria:

- Patients with confirmed type 2 diabetes mellitus for at least 2 months and treated
with metformin.

- Body mass index between ≥19 and ≤42 kg/m2.

Exclusion Criteria:

- Intake of another investigational drug within the last 30 days prior to enrolment.

- Clinically significant illness or clinically relevant trauma.